Latest Period
Q1 2026
Security Snapshot
Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) Institutional Ownership
CUSIP: 92511W207
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
39
Shares (Excl. Options)
4,777,869
Price
$5.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Symbol
- VRCA on Nasdaq
- Shares outstanding
- 8,810,762
- Price per share
- $6.21
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 4,777,869
- Total reported value
- $25,275,078
- % of total 13F portfolios
- 0%
- Share change
- -534,754
- Value change
- -$4,207,213
- Number of holders
- 39
- Price from insider filings
- $6.21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 92511W207.
- 39 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 49 to 39 between Q4 2025 and Q1 2026.
- Reported value moved from $43,155,907 to $25,275,078.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 39 institutions filings for Q1 2026.
Security key
92511W207
Latest holder period
Q1 2026
13F holders
39
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
VRCA full holder history
Verrica Pharmaceuticals Inc. SEC filings
Verrica Pharmaceuticals Inc. company facts
Verrica Pharmaceuticals Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92511W207:
Significant Owners of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Manning Paul B | 50% | $28,437,789 | 8,056,031 | Paul B Manning | 25 Nov 2025 | |||
| Caligan Partners LP | 10% | 0% | $43,635,492 | 6,503,054 | 0% | Caligan Partners LP | 26 Dec 2025 | |
| Affinity Asset Advisors, LLC | 5.5% | +0.6% | $7,346,762 | 884,172 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| ARMISTICE CAPITAL, LLC | 5% | -25% | $3,649,153 | -$1,656,149 | 439,657 | -31% | Armistice Capital, LLC | 31 Dec 2025 |
As of 31 Mar 2026, 39 institutional investors reported holding 4,777,869 shares of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA). This represents 54% of the company’s total 8,810,762 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Caligan Partners LP | 10% | 923,910 | 0% | 0.35% | $4,887,484 |
| Affinity Asset Advisors, LLC | 8% | 707,338 | 0% | 0.22% | $3,741,818 |
| CANNELL CAPITAL LLC | 7.8% | 685,123 | 2.4% | $3,624,301 | |
| ARMISTICE CAPITAL, LLC | 5.9% | 518,181 | -54% | 0.09% | $2,741,177 |
| Velan Capital Investment Management LP | 5.4% | 471,559 | 0% | 1.6% | $2,494,547 |
| BOOTHBAY FUND MANAGEMENT, LLC | 3.2% | 280,734 | 0% | 0.04% | $1,485,083 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1% | 188,758 | 0% | 0% | $998,530 |
| DAFNA Capital Management LLC | 1.7% | 153,712 | -11% | 0.18% | $813,136 |
| MARSHALL WACE, LLP | 1.6% | 140,497 | +65% | 0% | $743,229 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 138,917 | +105% | 0% | $734,965 |
| Stonepine Capital Management, LLC | 1.1% | 99,735 | -72% | 0.46% | $527,598 |
| Squarepoint Ops LLC | 0.85% | 75,208 | +126% | 0% | $397,850 |
| VANGUARD FIDUCIARY TRUST CO | 0.74% | 65,101 | 0% | 0% | $344,384 |
| TWO SIGMA INVESTMENTS, LP | 0.58% | 50,662 | -57% | 0% | $268,002 |
| JANE STREET GROUP, LLC | 0.56% | 49,211 | -52% | 0% | $260,327 |
| BlackRock, Inc. | 0.44% | 38,553 | +578% | 0% | $203,945 |
| RENAISSANCE TECHNOLOGIES LLC | 0.37% | 32,360 | +23% | 0% | $171,184 |
| NORTHERN TRUST CORP | 0.36% | 31,580 | +58% | 0% | $167,058 |
| STATE STREET CORP | 0.33% | 28,916 | +23% | 0% | $152,966 |
| Mariner, LLC | 0.28% | 24,544 | 0% | 0% | $129,838 |
| MORGAN STANLEY | 0.25% | 22,386 | +1.7% | 0% | $118,422 |
| Legacy Trust | 0.2% | 17,234 | 0% | 0.02% | $91,168 |
| Verdad Advisers, LP | 0.14% | 12,098 | 0.07% | $63,998 | |
| BECK MACK & OLIVER LLC | 0.14% | 12,000 | 0% | 0% | $63,480 |
| UBS Group AG | 0.05% | 4,270 | +17692% | 0% | $22,588 |